Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 112


Small-molecule IAP antagonists sensitize cancer cells to TRAIL-induced apoptosis: roles of XIAP and cIAPs.

Finlay D, Vamos M, González-López M, Ardecky RJ, Ganji SR, Yuan H, Su Y, Cooley TR, Hauser CT, Welsh K, Reed JC, Cosford ND, Vuori K.

Mol Cancer Ther. 2014 Jan;13(1):5-15. doi: 10.1158/1535-7163.MCT-13-0153. Epub 2013 Nov 5.


Cellular inhibitor of apoptosis 1 (cIAP-1) degradation by caspase 8 during TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis.

Guicciardi ME, Mott JL, Bronk SF, Kurita S, Fingas CD, Gores GJ.

Exp Cell Res. 2011 Jan 1;317(1):107-16. doi: 10.1016/j.yexcr.2010.10.005. Epub 2010 Oct 14.


Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatment.

Lu J, McEachern D, Sun H, Bai L, Peng Y, Qiu S, Miller R, Liao J, Yi H, Liu M, Bellail A, Hao C, Sun SY, Ting AT, Wang S.

Mol Cancer Ther. 2011 May;10(5):902-14. doi: 10.1158/1535-7163.MCT-10-0864. Epub 2011 Mar 3.


Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism.

Allensworth JL, Sauer SJ, Lyerly HK, Morse MA, Devi GR.

Breast Cancer Res Treat. 2013 Jan;137(2):359-71. doi: 10.1007/s10549-012-2352-6. Epub 2012 Dec 7.


Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells.

Metwalli AR, Khanbolooki S, Jinesh G, Sundi D, Shah JB, Shrader M, Choi W, Lashinger LM, Chunduru S, McConkey DJ, McKinlay M, Kamat AM.

Cancer Biol Ther. 2010 Nov 1;10(9):885-92. doi: 10.4161/cbt.10.9.13237. Epub 2010 Nov 1.


A Smac-mimetic sensitizes prostate cancer cells to TRAIL-induced apoptosis via modulating both IAPs and NF-kappaB.

Dai Y, Liu M, Tang W, Li Y, Lian J, Lawrence TS, Xu L.

BMC Cancer. 2009 Nov 6;9:392. doi: 10.1186/1471-2407-9-392.


Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib.

Lecis D, Drago C, Manzoni L, Seneci P, Scolastico C, Mastrangelo E, Bolognesi M, Anichini A, Kashkar H, Walczak H, Delia D.

Br J Cancer. 2010 Jun 8;102(12):1707-16. doi: 10.1038/sj.bjc.6605687. Epub 2010 May 11.


Smac mimetics in combination with TRAIL selectively target cancer stem cells in nasopharyngeal carcinoma.

Wu MS, Wang GF, Zhao ZQ, Liang Y, Wang HB, Wu MY, Min P, Chen LZ, Feng QS, Bei JX, Zeng YX, Yang D.

Mol Cancer Ther. 2013 Sep;12(9):1728-37. doi: 10.1158/1535-7163.MCT-13-0017. Epub 2013 May 22.


Sensitization of human bladder tumor cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis with a small molecule IAP antagonist.

Griffith TS, Kucaba TA, O'Donnell MA, Burns J, Benetatos C, McKinlay MA, Condon S, Chunduru S.

Apoptosis. 2011 Jan;16(1):13-26. doi: 10.1007/s10495-010-0535-3.


Targeted therapy of the XIAP/proteasome pathway overcomes TRAIL-resistance in carcinoma by switching apoptosis signaling to a Bax/Bak-independent 'type I' mode.

Gillissen B, Richter A, Richter A, Overkamp T, Essmann F, Hemmati PG, Preissner R, Belka C, Daniel PT.

Cell Death Dis. 2013 May 23;4:e643. doi: 10.1038/cddis.2013.67.


Bypassing the need for pre-sensitization of cancer cells for anticancer TRAIL therapy with secretion of novel cell penetrable form of Smac from hA-MSCs as cellular delivery vehicle.

Khorashadizadeh M, Soleimani M, Khanahmad H, Fallah A, Naderi M, Khorramizadeh M.

Tumour Biol. 2015 Jun;36(6):4213-21. doi: 10.1007/s13277-015-3058-2. Epub 2015 Jan 15.


Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the X-linked inhibitor of apoptosis protein.

Karikari CA, Roy I, Tryggestad E, Feldmann G, Pinilla C, Welsh K, Reed JC, Armour EP, Wong J, Herman J, Rakheja D, Maitra A.

Mol Cancer Ther. 2007 Mar;6(3):957-66. Epub 2007 Mar 5.


Cellular inhibitor of apoptosis (cIAP)-mediated ubiquitination of phosphofurin acidic cluster sorting protein 2 (PACS-2) negatively regulates tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) cytotoxicity.

Guicciardi ME, Werneburg NW, Bronk SF, Franke A, Yagita H, Thomas G, Gores GJ.

PLoS One. 2014 Mar 14;9(3):e92124. doi: 10.1371/journal.pone.0092124. eCollection 2014.


Wogonin enhances antitumor activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo through ROS-mediated downregulation of cFLIPL and IAP proteins.

Yang L, Wang Q, Li D, Zhou Y, Zheng X, Sun H, Yan J, Zhang L, Lin Y, Wang X.

Apoptosis. 2013 May;18(5):618-26. doi: 10.1007/s10495-013-0808-8.


Effect of the XIAP inhibitor Embelin on TRAIL-induced apoptosis of pancreatic cancer cells.

Mori T, Doi R, Kida A, Nagai K, Kami K, Ito D, Toyoda E, Kawaguchi Y, Uemoto S.

J Surg Res. 2007 Oct;142(2):281-6. Epub 2007 Jul 19.


Ceramide targets xIAP and cIAP1 to sensitize metastatic colon and breast cancer cells to apoptosis induction to suppress tumor progression.

Paschall AV, Zimmerman MA, Torres CM, Yang D, Chen MR, Li X, Bieberich E, Bai A, Bielawski J, Bielawska A, Liu K.

BMC Cancer. 2014 Jan 15;14:24. doi: 10.1186/1471-2407-14-24.


Cytoprotective effects of IAPs revealed by a small molecule antagonist.

Galbán S, Hwang C, Rumble JM, Oetjen KA, Wright CW, Boudreault A, Durkin J, Gillard JW, Jaquith JB, Morris SJ, Duckett CS.

Biochem J. 2009 Feb 1;417(3):765-71. doi: 10.1042/BJ20081677.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk